查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924675

人類狂犬病免疫球蛋白市場按配方、給藥途徑、通路、最終用戶和應用分類－2026-2032年全球預測

Human Rabies Immunoglobulin Market by Formulation, Route of Administration, Distribution Channel, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年人類狂犬病免疫球蛋白市場價值為2.5958億美元，預計到2026年將成長至2.8144億美元，年複合成長率為9.38%，到2032年將達到4.8644億美元。

關鍵市場統計數據
基準年 2025 2.5958億美元
預計年份：2026年 2.8144億美元
預測年份 2032 4.8644億美元
複合年成長率 (%) 9.38%

為醫療保健領導者提供關於人狂犬病免疫球蛋白的簡明權威指南，重點關注臨床優先事項、供應彈性以及營運要務。

人類狂犬病免疫球蛋白在全球感染疾病控制工具中佔據著至關重要的地位，在臨床上必須快速中和狂犬病毒的情況下，它能提供被動免疫。近年來，人們越來越關注供應的穩定性、暴露後管理的臨床指南以及低溫運輸物流的改進，這些因素共同影響醫療服務提供者和採購者的取得優先事項。在此背景下，治療環境受到生產複雜性、生物製藥的儲存要求以及協調一致的公共衛生應對措施的必要性等因素的影響，以確保及時為暴露者提供治療。

生產製造技術的進步、低溫運輸現代化以及不斷變化的監管要求如何重塑人類狂犬病免疫球蛋白的獲取和臨床應用？

人類狂犬病免疫球蛋白市場正經歷著變革性的轉變，這主要由技術、監管和供應鏈的發展所驅動，並正在重塑臨床和商業性實踐。生物製藥生產技術的進步提高了批次間的一致性，降低了污染風險；而製劑科學的創新，特別是那些能夠延長穩定性並簡化複溶的方法，正在重塑物流和床邊給藥方式。同時，不斷變化的藥品可追溯性和藥物監控監管要求，迫使生產商和經銷商投資建立更完善的品管系統。

評估美國狂犬病免疫球蛋白關稅調整對供應鏈和策略採購的營運和採購鏈影響

2025年美國關稅政策對人類狂犬病免疫球蛋白的整個供應鏈產生了累積影響，進而影響了籌資策略和採購風險狀況。更高的進口關稅和相關的合規成本增加促使相關人員尋求供應商多元化，並考慮近岸外包和區域夥伴關係以降低成本波動。因此，合約談判現在通常會考慮關稅、到岸成本波動以及跨境中斷應對計劃。

詳細的細分分析將臨床應用、製劑形式、給藥途徑、分銷管道和最終用戶對獲取和物流的影響聯繫起來。

細分市場分析揭示了不同類別（例如臨床用途、製劑形式、給藥途徑、通路和最終用戶）之間存在不同的需求促進因素和營運考慮。按應用領域分類，市場分為暴露後預防 (PEP) 和暴露前預防 (PEP)，這些場景呈現出不同的臨床緊急程度，從而影響庫存優先級和臨床醫生培訓需求。依製劑形式，市場分為冷凍乾燥製劑及液體製劑，穩定性及低溫運輸會影響設施儲存及保存期限管理。依給藥途徑分類，市場分為肌肉注射和靜脈注射，給藥途徑的選擇會影響產品包裝、給藥通訊協定以及照護端所需的護理技能。

美洲、歐洲、中東和非洲以及亞太地區在營運和監管方面的區域差異將決定供應、分銷和臨床准入策略。

區域趨勢對美洲、歐洲、中東和非洲以及亞太地區的供應鏈設計、監管互動和臨床應用模式均有顯著影響。在美洲，整合的醫院網路和集中採購機制促使企業更加重視供應可靠性和嚴格遵守低溫運輸標準，從而鼓勵與成熟的生物製藥生產商和專業分銷商開展合作。在歐洲、中東和非洲地區，監管環境各不相同，一些市場推行統一的藥物監測通訊協定，而另一些市場則優先考慮本地生產獎勵以改善藥物可及性，這影響了採購週期和供應商選擇。

透過配方創新、卓越的物流和貫穿整個價值鏈的合規監管，採取策略性企業行動，使製造商和經銷商脫穎而出。

在企業層面，企業活動正呈現分化趨勢：一部分企業專注於專業的生物製藥生產，而另一部分企業則優先考慮卓越的分銷和物流，以確保及時將藥品送達患者手中。投資先進配方和穩定性技術的製造商正致力於降低低溫運輸風險，提升產品可用性。同時，專注於分銷的企業正在加強履約網路、庫存可視性和低溫運輸監控能力，以減少廢棄物和前置作業時間風險。技術先進的製造企業與物流專家之間的策略聯盟日益普遍，從而能夠提供兼顧臨床療效和營運可靠性的整合解決方案。

為行業領導者提供切實可行的、優先考慮的建議，以加強供應鏈的連續性，簡化臨床服務流程，並調整採購方式以適應不斷變化的貿易和監管壓力。

行業領導者應優先採取措施，增強供應鏈韌性，簡化臨床管理，並使商業策略與不斷發展的採購慣例實踐相適應。首先，透過投資於製劑穩定性和包裝，降低低溫運輸的依賴性，將顯著改善資源匱乏環境下的藥品獲取，並降低機構採購者的整體營運風險。其次，與物流供應商夥伴關係，實施即時溫度監控和即時補貨機制，將減少浪費，並為醫院和診所提供可預測的訂購週期。第三，擴大臨床醫師訓練範圍，並完善肌肉注射和靜脈注射的床邊通訊協定，將減少預防性給藥的延誤，並提高指引的遵從性。

透明嚴謹的調查方法結合了相關人員訪談、文獻綜述和情境分析，以檢驗營運結果和建議。

本研究結合了對關鍵相關人員的訪談、文獻綜述以及對臨床和物流變量的系統分析，以全面了解狂犬病免疫球蛋白在人用領域的現狀。一級資訊來源包括對臨床醫生、採購專業人員、法規事務負責人和供應鏈經理的訪談，以收集有關現場操作挑戰和決策標準的資訊。次要資訊來源包括同儕審查的臨床指南、監管文件以及關於生物製藥生產、低溫運輸最佳實踐和給藥通訊協定的技術報告，從而能夠將從業人員的觀點與已記錄的標準進行交叉檢驗。

總之，確保預防性取得需要採取綜合方法，強調製造、分銷、臨床工作流程和採購等各環節的系統完整性。

總之，確保可靠地獲取人類狂犬病免疫球蛋白需要生產、分銷、臨床實踐和採購政策等各環節的協調努力。製劑和低溫運輸技術的進步有助於降低物流風險，而現代化的通路和數位化訂購平台則提高了補貨的透明度和速度。同時，不斷變化的貿易政策和監管預期要求採取積極主動的籌資策略、加強供應商實質審查以及靈活調整契約，以維持醫療服務的連續性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 人類狂犬病免疫球蛋白市場（依產品分類）

  • 冷凍乾燥製劑
  • 液體

9. 依給藥途徑分類的人類狂犬病免疫球蛋白市場

  • 肌肉內注射
  • 靜脈注射

10. 人狂犬病免疫球蛋白市場（依分銷管道分類）

  • 線上
    • 製造商官方網站
    • 電子商務入口網站
  • 離線

11. 依最終使用者分類的人類狂犬病免疫球蛋白市場

  • 診所
  • 政府衛生中心
  • 醫院

12. 按應用分類的人類狂犬病免疫球蛋白市場

  • 暴露後預防
  • 暴露前預防

13. 各地區人類狂犬病免疫球蛋白市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

14. 人類狂犬病免疫球蛋白市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國狂犬病免疫球蛋白市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國人類狂犬病免疫球蛋白市場

17. 中國狂犬病免疫球蛋白市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bharat Serum
  • China Biologic Products Holdings Inc.
  • China National Biotec Group
  • CSL Behring LLC
  • Grifols, SA
  • Kamada Ltd.
  • Kedrion SpA
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt. Ltd.
  • Shanghai RAAS
  • Shuanglin Bio
  • Sichuan Yuanda Shuyang
  • VINS
  • Weiguang Bio
  • Zydus Lifesciences Ltd.
Product Code: MRR-7A380DA7C418

The Human Rabies Immunoglobulin Market was valued at USD 259.58 million in 2025 and is projected to grow to USD 281.44 million in 2026, with a CAGR of 9.38%, reaching USD 486.44 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 259.58 million
Estimated Year [2026] USD 281.44 million
Forecast Year [2032] USD 486.44 million
CAGR (%) 9.38%

A concise and authoritative orientation to human rabies immunoglobulin focusing on clinical priorities, supply resilience, and operational imperatives for healthcare leaders

Human rabies immunoglobulin occupies a vital place in the global infectious disease toolkit, providing passive immunity where prompt neutralization of rabies virus is clinically imperative. Recent years have seen heightened attention to supply resilience, clinical guidelines for post-exposure management, and improvements in cold-chain logistics that collectively influence how providers and purchasers prioritize access. Against this backdrop, the therapeutic landscape is shaped by manufacturing complexity, biologic storage requirements, and the need for coordinated public health responses to ensure timely administration to exposed individuals.

Clinicians and health system leaders increasingly weigh the trade-offs between formulation stability, route of administration, and distribution pathways when designing prophylaxis programs. As contemporary clinical practice evolves, so do procurement strategies that emphasize reliability and traceability alongside clinical efficacy. In addition, regulatory harmonization efforts and international collaboration on rabies control inform procurement protocols and usage patterns. Consequently, stakeholders must balance immediate clinical imperatives against longer-term investments in manufacturing capacity, cold-chain infrastructure, and clinician education to close gaps in prophylactic delivery.

How manufacturing advances, cold-chain modernization, and evolving regulatory expectations are reshaping access and clinical use of human rabies immunoglobulin

The landscape for human rabies immunoglobulin is undergoing transformative shifts driven by technological, regulatory, and supply-chain developments that are redefining clinical and commercial practice. Advances in biologics manufacturing techniques have improved batch consistency and lowered contamination risk, while innovations in formulation science-particularly approaches that extend stability or simplify reconstitution-are reshaping logistics and bedside administration. Concurrently, evolving regulatory expectations around traceability and pharmacovigilance are prompting manufacturers and distributors to invest in more robust quality management systems.

Supply-chain modernization is another vector of change, as integrated cold-chain monitoring and distributed warehousing reduce the lead times and spoilage risks that historically constrained access. Meanwhile, digital channels for ordering and inventory management are gaining traction among institutional buyers, enabling rapid replenishment and improved visibility across networks. On the clinical front, guideline updates and heightened awareness among emergency care providers are increasing the urgency of accessible passive immunization for exposed patients. Taken together, these shifts create opportunities for differentiated product positioning that emphasize reliability, ease of use, and alignment with contemporary standards of care.

Assessing the cascading operational and procurement consequences of the United States tariff adjustments on rabies immunoglobulin supply chains and strategic sourcing

Tariff measures implemented in the United States in 2025 have exerted cumulative effects across the supply chain for human rabies immunoglobulin, influencing sourcing strategies and procurement risk profiles. Higher import duties and associated compliance costs have increased the incentive for stakeholders to diversify supplier bases and consider nearshoring or regional partnerships to mitigate cost volatility. As a result, contract negotiations now routinely factor in customs duties, landed-cost variability, and contingency planning for cross-border disruptions.

These tariff-driven dynamics have also accelerated conversations about vertical integration and local manufacturing capacity among manufacturers and large institutional buyers. In parallel, distributors and hospital procurement teams are re-evaluating inventory buffers and lead-time assumptions to absorb pricing and freight variability. Importantly, while tariffs impose additional cost pressures, they also catalyze investments in domestic regulatory alignment and quality assurance programs to support any expanded local production. The net operational effect is a shift toward more sophisticated procurement frameworks that emphasize supplier redundancy, transparent cost modeling, and scenario planning to preserve clinical access amid an increasingly complex trade environment.

In-depth segmentation insights connecting clinical application, formulation, administration route, channel distribution, and end-user implications for access and logistics

Segmentation analysis reveals differentiated demand drivers and operational considerations across distinct clinical, formulation, administration, distribution, and end-user categories. Based on Application, market is studied across Post Exposure Prophylaxis and Pre Exposure Prophylaxis, and these use-cases present divergent clinical urgency profiles that shape inventory prioritization and clinician training needs. Based on Formulation, market is studied across Freeze Dried and Liquid, with stability and cold-chain implications influencing storage practices and shelf-life management for institutions. Based on Route of Administration, market is studied across Intramuscular and Intravenous, and the choice between these routes affects product packaging, administration protocols, and nursing competencies required at the point of care.

Additionally, based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, with the Online Pharmacy further studied across Manufacturer Portal and Third Party Portal, and the Retail Pharmacy further studied across Chain Pharmacy and Independent Pharmacy; distribution channel selection has operational consequences for order fulfillment, traceability, and patient access pathways. Finally, based on End User, market is studied across Clinics, Government Health Centers, and Hospitals, and each end-user type places different demands on procurement cadence, cold-storage infrastructure, and clinical education. Consequently, segmentation highlights where investments in formulation innovation, administration training, and distribution optimization will yield the highest operational returns.

Regional operational and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine supply, distribution, and clinical access strategies

Regional dynamics exert a pronounced influence on supply-chain design, regulatory interfaces, and clinical adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated hospital networks and centralized procurement mechanisms drive an emphasis on supply reliability and compliance with stringent cold-chain standards, encouraging partnerships with established biologics manufacturers and specialized distributors. Across Europe, Middle East & Africa, the regulatory landscape shows heterogeneity, with some markets advancing harmonized pharmacovigilance protocols while others prioritize local manufacturing incentives to enhance access, which in turn affects procurement timelines and supplier selection.

Asia-Pacific exhibits a blend of high-capacity manufacturing hubs and rapidly modernizing distribution channels, prompting stakeholders to optimize cross-border logistics and leverage regional production capabilities to meet proximal demand. These regional patterns interact with global trade policies, cold-chain infrastructure maturity, and the prevalence of clinical guidelines, resulting in differentiated strategies for stocking, ordering cadence, and clinician readiness. Consequently, stakeholders must adopt region-specific approaches that align distribution models, regulatory engagement, and workforce training with local operational realities to sustain continuous access to passive immunization.

Strategic company behaviors that differentiate manufacturers and distributors through formulation innovation, logistical excellence, and regulatory alignment across the value chain

Company-level activity demonstrates a split between organizations focusing on specialized biologics manufacturing and those prioritizing distribution and logistical excellence to ensure timely delivery to point-of-care settings. Manufacturers investing in advanced formulation and stability technologies are positioning to reduce cold-chain fragility and improve product usability, whereas distribution-focused firms are enhancing their fulfillment networks, inventory visibility, and cold-chain monitoring capabilities to reduce spoilage and lead-time risk. Strategic collaborations between technology-forward manufacturers and logistics specialists are increasingly common, enabling integrated solutions that address both clinical efficacy and operational reliability.

Furthermore, companies with established regulatory affairs expertise tend to accelerate market entry in complex jurisdictions by aligning with local surveillance and safety reporting expectations. Partnerships with hospitals, government health centers, and clinics to pilot new administration protocols or dispenser-ready formats are also shaping competitive differentiation. In aggregate, organizational strategies revolve around securing supply continuity, demonstrating product robustness under real-world conditions, and streamlining the interface between procurement teams and clinical end-users to reduce barriers to timely prophylaxis.

Practical and prioritized recommendations for industry leaders to strengthen supply continuity, streamline clinical delivery, and align procurement with evolving trade and regulatory pressures

Industry leaders should prioritize actions that strengthen supply resilience, simplify clinical administration, and align commercial strategies with evolving procurement practices. First, investments in formulation stability and packaging formats that reduce cold-chain dependency will materially improve access in resource-constrained settings and lower total operational risk for institutional buyers. Second, building partnerships with logistics providers to deploy real-time temperature monitoring and just-in-time replenishment frameworks will limit spoilage and support predictable ordering cycles for hospitals and clinics. Third, expanding clinician training and point-of-care protocols for both intramuscular and intravenous administration will reduce delays in prophylaxis delivery and increase adherence to guidance.

In parallel, stakeholders should reassess contracting approaches to incorporate clauses that address tariff-induced cost variability and to foster supplier redundancy. Engaging with regulatory stakeholders early to clarify traceability and pharmacovigilance expectations will expedite approvals and support safer use. Finally, piloting digital ordering portals-either manufacturer-operated or third-party-can reveal efficiencies in fulfillment while improving transparency for chain and independent retail pharmacies. Taken together, these measures will help organizations convert analytical insight into operational improvements that protect patient outcomes and optimize resource utilization.

A transparent and rigorous research methodology combining stakeholder interviews, literature synthesis, and scenario analysis to validate operational insights and recommendations

This research synthesizes primary stakeholder interviews, secondary literature review, and a structured analysis of clinical and logistical variables to produce a comprehensive view of the human rabies immunoglobulin landscape. Primary inputs included consultations with clinicians, procurement specialists, regulatory affairs professionals, and supply-chain managers to capture on-the-ground operational challenges and decision criteria. Secondary inputs encompassed peer-reviewed clinical guidance, regulatory documents, and technical reports related to biologics manufacturing, cold-chain best practices, and administration protocols, enabling cross-validation of practitioner perspectives and documented standards.

Qualitative synthesis techniques were applied to distill recurring themes and to identify divergence between regions and end-user types. Scenario analysis was used to explore the operational implications of trade policy shifts and technological adoption, while triangulation across sources ensured robustness of insight. Throughout the research process, emphasis was placed on transparency of assumptions, reproducibility of findings, and the practical applicability of recommendations to stakeholders across hospitals, clinics, government health centers, and distribution networks.

Concluding synthesis emphasizing systems-level alignment of manufacturing, distribution, clinical workflows, and procurement to safeguard prophylactic access

In conclusion, ensuring reliable access to human rabies immunoglobulin requires coordinated action across manufacturing, distribution, clinical practice, and procurement policy. Advances in formulation and cold-chain technologies offer a pathway to reduce logistical fragility, while modernized distribution channels and digital ordering platforms can improve transparency and speed of replenishment. At the same time, trade policy shifts and regulatory expectations necessitate proactive sourcing strategies, enhanced supplier due diligence, and adaptive contracting to preserve continuity of care.

Ultimately, the convergence of these factors underscores the importance of systems thinking: aligning product design with administration workflows, distribution capabilities, and regional regulatory conditions is essential to closing gaps in prophylactic delivery. Stakeholders that invest in stability-enhancing formulations, robust logistics partnerships, and clinician readiness programs will be best positioned to maintain timely access and to translate technical innovation into improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Rabies Immunoglobulin Market, by Formulation

  • 8.1. Freeze Dried
  • 8.2. Liquid

9. Human Rabies Immunoglobulin Market, by Route of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Human Rabies Immunoglobulin Market, by Distribution Channel

  • 10.1. Online
    • 10.1.1. Manufacturer Websites
    • 10.1.2. eCommerce Portals
  • 10.2. Offline

11. Human Rabies Immunoglobulin Market, by End User

  • 11.1. Clinics
  • 11.2. Government Health Centers
  • 11.3. Hospitals

12. Human Rabies Immunoglobulin Market, by Application

  • 12.1. Post Exposure Prophylaxis
  • 12.2. Pre Exposure Prophylaxis

13. Human Rabies Immunoglobulin Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Human Rabies Immunoglobulin Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Human Rabies Immunoglobulin Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Human Rabies Immunoglobulin Market

17. China Human Rabies Immunoglobulin Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bharat Serum
  • 18.6. China Biologic Products Holdings Inc.
  • 18.7. China National Biotec Group
  • 18.8. CSL Behring LLC
  • 18.9. Grifols, S.A.
  • 18.10. Kamada Ltd.
  • 18.11. Kedrion S.p.A.
  • 18.12. Sanofi Pasteur S.A.
  • 18.13. Serum Institute of India Pvt. Ltd.
  • 18.14. Shanghai RAAS
  • 18.15. Shuanglin Bio
  • 18.16. Sichuan Yuanda Shuyang
  • 18.17. VINS
  • 18.18. Weiguang Bio
  • 18.19. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ECOMMERCE PORTALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ECOMMERCE PORTALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ECOMMERCE PORTALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY GOVERNMENT HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY GOVERNMENT HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY GOVERNMENT HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY POST EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY PRE EXPOSURE PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA HUMAN RABIES IMMUNOGLOBULIN MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)